Sivik Global Healthcare LLC Acquires New Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Sivik Global Healthcare LLC bought a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 205,241 shares of the company's stock, valued at approximately $1,344,000. Sivik Global Healthcare LLC owned about 0.08% of Maravai LifeSciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC raised its stake in shares of Maravai LifeSciences by 99.9% in the third quarter. Signaturefd LLC now owns 3,364 shares of the company's stock worth $34,000 after buying an additional 1,681 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Maravai LifeSciences by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company's stock valued at $34,000 after purchasing an additional 1,662 shares in the last quarter. Pinnacle Associates Ltd. bought a new position in shares of Maravai LifeSciences in the fourth quarter worth approximately $69,000. Ieq Capital LLC purchased a new stake in shares of Maravai LifeSciences in the third quarter worth $110,000. Finally, Advisor Partners II LLC bought a new stake in shares of Maravai LifeSciences during the 3rd quarter valued at $115,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on MRVI shares. Stifel Nicolaus decreased their target price on Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, February 23rd. Royal Bank of Canada lifted their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd. Finally, Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They set a "buy" rating and a $15.00 target price for the company. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Maravai LifeSciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.56.

Maravai LifeSciences Trading Up 4.5 %

Maravai LifeSciences stock traded up $0.35 during midday trading on Tuesday, reaching $8.20. 2,284,856 shares of the stock traded hands, compared to its average volume of 2,532,972. The firm has a market cap of $2.06 billion, a PE ratio of -9.11 and a beta of 0.01. Maravai LifeSciences Holdings, Inc. has a 12-month low of $4.52 and a 12-month high of $16.62. The company has a current ratio of 8.00, a quick ratio of 7.41 and a debt-to-equity ratio of 0.70. The company has a 50-day simple moving average of $7.89 and a two-hundred day simple moving average of $6.66.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $74.14 million for the quarter, compared to analysts' expectations of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. Research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.